In the Media
Are you looking for the latest media coverage of the BioMed X, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Germany-based BioMed X Institute completed its first joint research project in neuroscience with Boehringer Ingelheim.
BioSpace
Following completion of the project, the research has now transitioned to BI for additional development. The team has validated candidate genes in several biological systems, and as a key achievement, proposes novel glial-specific drug targets for therapy of depression.
The Biomed X Institute, of Heidelberg, Germany, said it completed its first joint research neuroscience project with Boehringer Ingelheim GmbH, of Ingelheim, Germany.
BioWorld
The project launched in 2016 to uncover the contribution of astrocytes, a subtype of glial cells, to molecular phenotypes in depression.
Talenten auf der Spur
DER SPIEGEL, special section 'Starkes Land Baden-Württemberg' (print edition for Baden Württemberg)
Careers in the industry: The region around Heidelberg attracts top-class specialists from all over the world with quality of life, a lively international atmosphere and a wide range of jobs in research and industry. (German only)
Biotech in Deutschland – eine Branche weit unter Potenzial
BioSpektrum
Als bedeutender Forschungszweig in der Medizin liefert die Biotechnologie wichtige Impulse für neue Wirkstoffe, Medikamente und Diagnostika. Trotz des großen Innovationspotenzials in Deutsch land liegen hier die Investitionen in die Translation von Forschungsergebnissen in marktfähige Produkte weit hinter den internationalen Spitzenstandorten Silicon valley und Boston.
BioMed X Enstitüsü’nden Dr. Ebru Ercan Herbst: Şizofreni her 100 insanda 1’inde görülüyor
Independent Türkçe
From the BioMed X Institute, Dr. Ebru Ercan Herbst: Schizophrenia is seen in 1 in every 100 people. Schizophrenia, which starts between the ages of 16 and 30, causes hallucinations, delusions, and disordered thinking.
Leveraging synergies in pre-clinical biomedical R&D – pharmaceutical companies benefit from new innovation models
Word Pharma Today
As the complexity of pharmaceutical research and development increases constantly, its innovation productivity defined as the successful approval and launch of truly novel drugs and therapies, has declined since years.
BioMed X Reaches Milestone in Respiratory Disease Research Collaboration with Boehringer Ingelheim
BioSpace
BioMed X announced today the successful completion of their first joint research project with Boehringer Ingelheim in the fields of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
15 Most Promising Biotech Startups in Europe – 2019
Startup City
As new technologies emerge, numerous biotech startups are launched across Europe every year. With specialized venture capital firms and technology companies pouring money into the sector, biotech startups now attract record amount of investment.